Cost-effectiveness Analysis of Eribulin Versus Dacarbazine in Patients with Advanced Liposarcoma

Overview

Journal Sci Rep

Date 2025 Jan 15

PMID 39814865

Authors

Miaomiao Zhang

Jinlong Huang

Xiaochun Zheng

Ping Huang

Xiuli Yang

Affiliations

Soon will be listed here.

Abstract

A subgroup analysis of a randomized study demonstrated that patients with advanced or metastatic liposarcoma treated with eribulin had longer overall survival and progression-free survival compared to those treated with dacarbazine, suggesting eribulin as a therapeutic option for advanced liposarcoma. Therefore, this study aims to evaluate the cost-effectiveness of eribulin versus dacarbazine in the treatment of advanced liposarcoma. We established a 10-year Markov model to compare the cost-effectiveness of eribulin and dacarbazine regimens. Clinical data were sourced from a subgroup analysis of a multicenter, randomized, open-label phase 3 trials. Quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were computed. The total cost of the dacarbazine scheme was $10,895.558, with a QALY of 0.533. In contrast, the total cost of the eribulin scheme was $16,961.891, with a QALY of 0.698. The ICER between the eribulin and dacarbazine schemes was $36,736.467, which is below the willingness-to-pay (WTP) threshold in China ($37,877.469). From the perspective of the Chinese healthcare system, eribulin is cost-effective compared to dacarbazine at the WTP threshold.

References

Delea T, Amdahl J, Nakhaipour H, Manson S, Wang A, Fedor N . Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada. Curr Oncol. 2014; 21(6):e748-59. PMC: 4257119. DOI: 10.3747/co.21.1899. View

Eichler H, Kong S, Gerth W, Mavros P, Jonsson B . Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health. 2004; 7(5):518-28. DOI: 10.1111/j.1524-4733.2004.75003.x. View

Lin J, Fang Q, Zheng X . Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China. PLoS One. 2023; 18(2):e0281402. PMC: 9904460. DOI: 10.1371/journal.pone.0281402. View

Amdahl J, Manson S, Isbell R, Chit A, Diaz J, Lewis L . Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom. Sarcoma. 2014; 2014:481071. PMC: 4082932. DOI: 10.1155/2014/481071. View

Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R . Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995; 13(7):1537-45. DOI: 10.1200/JCO.1995.13.7.1537. View

Demetri G, Schoffski P, Grignani G, Blay J, Maki R, Van Tine B . Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol. 2017; 35(30):3433-3439. DOI: 10.1200/JCO.2016.71.6605. View

Chen X, Liang W, Wan N, Zhang L, Yang Y, Jiang J . Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 2019; 94:80-85. DOI: 10.1016/j.oraloncology.2019.04.022. View

Demetri G, von Mehren M, Jones R, Hensley M, Schuetze S, Staddon A . Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2015; 34(8):786-93. PMC: 5070559. DOI: 10.1200/JCO.2015.62.4734. View

Soini E, Garcia San Andres B, Joensuu T . Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information. Ann Oncol. 2010; 22(1):215-223. PMC: 3003615. DOI: 10.1093/annonc/mdq339. View

10.

Zhao X, Li P, Huang X, Chen L, Liu N, She Y . Prognostic factors predicting the postoperative survival period following treatment for primary retroperitoneal liposarcoma. Chin Med J (Engl). 2015; 128(1):85-90. PMC: 4837826. DOI: 10.4103/0366-6999.147822. View

11.

Le Q . Structural Uncertainty of Markov Models for Advanced Breast Cancer: A Simulation Study of Lapatinib. Med Decis Making. 2016; 36(5):629-40. DOI: 10.1177/0272989X15622643. View

12.

Patel S, Vadhan-Raj S, Burgess M, Plager C, Papadopolous N, Jenkins J . Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998; 21(3):317-21. DOI: 10.1097/00000421-199806000-00025. View

13.

Murray C, Evans D, Acharya A, Baltussen R . Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000; 9(3):235-51. DOI: 10.1002/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o. View

14.

Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere A, Peoch M, Istier L . Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011; 6(8):e20294. PMC: 3149593. DOI: 10.1371/journal.pone.0020294. View

15.

Zucali P, Bertuzzi A, Soto Parra H, Campagnoli E, Quagliuolo V, Santoro A . The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas. Invest New Drugs. 2007; 26(2):175-81. DOI: 10.1007/s10637-007-9086-z. View

16.

Liao M, Jiang Q, Hu H, Han J, She L, Yao L . Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China. J Med Econ. 2019; 22(6):584-592. DOI: 10.1080/13696998.2019.1588125. View

17.

Van Glabbeke M, Van Oosterom A, Oosterhuis J, Mouridsen H, Crowther D, Somers R . Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and.... J Clin Oncol. 1999; 17(1):150-7. DOI: 10.1200/JCO.1999.17.1.150. View

18.

Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, Martin J, Martinez-Trufero J, Casado A . Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011; 29(18):2528-33. DOI: 10.1200/JCO.2010.33.6107. View

19.

Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S . Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer. 2014; 110(6):1497-505. PMC: 3960630. DOI: 10.1038/bjc.2014.80. View

20.

Tremblay G, Majethia U, Kontoudis I, De Rosendo J . Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy. J Health Econ Outcomes Res. 2023; 3(2):180-193. PMC: 10471375. DOI: 10.36469/9834. View